Oslo, Norway, August 15, 2022 /PRNewswire/ — Lytix Biopharma is pleased to announce that it will host a Capital Markets Day for investors, analysts and the media on Wednesday, June 1, 2022
- The event will be open to physical participation in Oslo, Norway, as well as a live webcast. It is scheduled to start at 2:00 p.m. CET and should last around two hours, including questions and answers.
- Speakers will be Ted WhiteCEO of Verrica Pharmaceuticals Inc. (“Verrica”), Gary GoldenbergCMO of Verrica, Aurélien Marabelle, visiting professor at Stanford University and an internationally recognized expert in the treatment of intratumoral cancer, and Øystein Rekdal, CEO of Lytix Biopharma.
- Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize its lead compound, LTX-315, for dermatological oncology conditions, and the first patient has been dosed in Verrica’s Phase II study evaluating LTX-315 for the intratumoral treatment of basal cell carcinoma (skin cancer). At the CMD, the focus will be on the rationale and the current state of the art regarding the intratumoral treatment of cancer patients. Above all, the agreement between Verrica and Lytix and the commercial opportunity and clinical value of LTX-315 in the treatment of cellular carcinomas will be highlighted.
Further details on the agenda and how to register will follow.
Ole Peter NordbyHead of IR & Head of Communication
E-mail: [email protected]
Mobile: +47 412 87 179
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Lytix Biopharma AS